Teranol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Teranol

Property Description
Active ingredient Ketorolac tromethamine
Form Tablet, injectable solution, nasal spray, ophthalmic solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Short-term management of acute, moderately severe pain
Origin Synthetic organic compound

Teranol: Classification, Composition, and Identity

Teranol is a prescription-only medication classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and a potent non-narcotic analgesic. The drug's action is solely attributed to its active ingredient, Ketorolac tromethamine, a synthetic compound belonging to the pyrrolo-pyrrole chemical group. The specific molecular structure of Ketorolac grants it an analgesic potency that is clinically recognized as significant, often being reserved for pain levels that exceed the relief typically offered by common, over-the-counter NSAIDs. This formulation’s status as a non-narcotic agent provides a critical alternative in managing pain without the central nervous system effects associated with controlled substances.


Active Substance and General Purpose

The primary purpose of Teranol is the short-term management of moderately severe acute pain. The Ketorolac tromethamine achieves this by acting as a non-selective inhibitor of the cyclooxygenase (COX) enzyme system, which blocks the synthesis of prostaglandins. Prostaglandins are key chemicals that promote both pain signaling and inflammation. This targeted chemical action allows the medicine to effectively interrupt the transmission of pain signals and reduce physical discomfort at its source, such as pain experienced immediately following surgical procedures.


Available Forms of Ketorolac

Ketorolac is distinguished by its availability across multiple dosage forms, offering substantial flexibility in administration. These preparations include an oral tablet, a sterile injectable solution for parenteral (intramuscular and intravenous) administration, a nasal spray, and an ophthalmic solution. This versatility allows the drug to be administered parenterally for rapid systemic effects in a clinical setting or via localized topical application to the eye, depending on the specific requirement of the patient's condition.

What side effects are possible with Teranol?

Possible Side Effects and Safety Information

The safety profile of Teranol (Ketorolac tromethamine), as a potent Nonsteroidal Anti-inflammatory Drug (NSAID), is characterized by serious risks and explicit limitations documented by regulatory authorities. The overall risk of serious adverse events is noted to increase with both dose and duration of exposure.

Serious Adverse Reactions and Duration Constraint

Official labeling highlights severe, potentially fatal, risks primarily involving major organ systems. These include Gastrointestinal Risk (e.g., peptic ulcers, bleeding, or perforation) and Cardiovascular Thrombotic Events (e.g., myocardial infarction or stroke). Acute renal failure and severe hypersensitivity reactions, such as anaphylaxis and Stevens-Johnson syndrome, are also documented as serious adverse reactions.

Regulatory agencies impose a critical constraint: the total combined duration of systemic use (parenteral and oral) must not exceed five days to minimize the risk of serious adverse events. Gastrointestinal events can occur at any time during treatment.

Frequency-Classified Effects

Common adverse reactions are officially classified based on their incidence in clinical data:

System Organ Class Incidence >10% (Very Common) Incidence 1% to 10% (Common)
Gastrointestinal Abdominal pain, Dyspepsia, Nausea Diarrhea/Constipation, Vomiting
Nervous System Headaches Dizziness, Drowsiness

Population-Specific Safety

Older adults are identified as being at a greater risk for serious gastrointestinal adverse events. Use is contraindicated in individuals with advanced renal impairment and during labor and delivery. The concurrent use of Teranol with other NSAIDs is strictly contraindicated due to the cumulative risk of severe side effects.

Overdose and Emergency Response

Documented Overdose Manifestations

An overdose of Teranol (Ketorolac tromethamine) is officially documented to present with signs of systemic distress and central nervous system involvement. Documented clinical manifestations include lethargy, drowsiness, nausea, vomiting, and epigastric pain, alongside signs of potential GI bleeding and hyperventilation. Severe or life-threatening outcomes listed in official prescribing information involve major organ systems, specifically acute renal failure, hypertension, respiratory depression, and coma. Anaphylactoid reactions are also listed as a possibility.

Emergency Action and Supportive Management

The regulatory consensus dictates that patients should be managed by symptomatic and supportive care. Immediate medical help is required, particularly following a large oral overdose—defined as five to ten times the usual dose—or upon the appearance of severe symptoms.

Since no specific antidotes are known or described for Ketorolac tromethamine, management focuses entirely on supportive measures. These officially described procedures may include the administration of activated charcoal and/or an osmotic cathartic when indicated. Dosage guidance for supportive agents like activated charcoal may differ between adults and children. Overdose symptoms are stated to be generally reversible with supportive care.

Therapeutic Uses of Teranol

What Teranol Treats: Main Uses and Benefits

Teranol is commonly used to help with the short-term management of moderately severe acute pain, offering symptomatic relief across therapeutic domains where symptoms may interfere with daily functioning. This medication is applied in clinical settings where short-term symptom management is appropriate, especially when discomfort arises from postoperative pain, acute musculoskeletal injury, and certain types of visceral pain.


Key Therapeutic Focus

The medicine is applied in clinical settings that involve acute or unstable symptom patterns, especially when symptoms are driven by sudden, intense physical discomfort or are related to inflammatory or irritative states. It provides supportive symptomatic relief, used when groups of symptoms appear suddenly or fluctuate. It is considered relevant in contexts involving heightened systemic burden for adult patients, often during recovery from surgical procedures.


Quick Fact: Relief for Intense Acute Pain

This medication is relevant when supportive symptom management is appropriate, assisting with maintaining functional stability when symptoms become pronounced and disruptive. It supports patients during episodes of heightened discomfort.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Teranol (Ketorolac tromethamine) is officially indicated only for adult patients (typically ge 16 or ge 17 years of age) for the short-term management of moderately severe acute pain. Use in pediatric patients is not established and is generally not recommended by regulatory authorities.

Absolute Contraindications

The medicine is strictly contraindicated and must not be used by certain populations:

  • Patients with a history of active peptic ulcer disease or gastrointestinal bleeding.
  • Individuals with advanced renal impairment, severe uncontrolled heart failure, or severe hepatic impairment.
  • Patients with suspected or confirmed bleeding disorders, including cerebrovascular bleeding.
  • Those with a known hypersensitivity or allergic reaction (such as asthma or urticaria) to aspirin or any other NSAID.
  • Women who are breastfeeding, or women in the setting of labor and delivery.
  • Patients undergoing treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.

Use with Conditional Restrictions

Older adults (ge 65 years) and patients under mathbf50 kg are designated as special populations in regulatory documents. Use in these groups requires caution and is subject to specific regulatory limitations, including adherence to a restricted maximum daily dose and reduced duration of use. Similarly, use is conditionally restricted in patients with mild or moderate organ impairment and must be strictly monitored.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Teranol (Ketorolac tromethamine) around the risk of pharmacokinetic alteration and pharmacodynamic synergy, which can lead to specific mandatory restrictions.

Formal Contraindications

Co-administration is strictly contraindicated with certain medicines due to documented interaction outcomes:

  • Aspirin and other Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Prohibition due to the cumulative risk of serious NSAID-related side effects.
  • Probenecid: Contraindicated because it significantly reduces Ketorolac’s renal clearance, resulting in increased plasma exposure.
  • Pentoxifylline: Contraindicated due to the documented increase in bleeding risk.

Clinically Significant Interactions

Interactions with other drug classes primarily focus on either additive effects or altered drug clearance:

  • Pharmacodynamic Risk: Combining Teranol with Anticoagulants (e.g., Warfarin), Antiplatelet agents, and SSRIs is associated with an increased risk of serious hemorrhage. Co-administration with ACE Inhibitors and Diuretics may increase the risk of renal impairment and reduce the blood pressure lowering effect of those medicines.
  • Exposure Alteration: Teranol reduces the renal clearance of co-administered Lithium and Methotrexate, which results in increased plasma concentrations and potential toxicity of these substances.

Food and Substance Interactions

Ingestion of the oral formulation with a high-fat meal decreases the peak concentration (Cmax) and delays the time-to-peak concentration (Tmax). Consumption of Alcohol is documented to increase the risk of stomach bleeding.

Mechanism of Action

Inhibition of Cyclooxygenase (COX) Enzymes

Teranol's mechanism is defined by the non-selective competitive inhibition of the Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This molecular action directly intervenes in the arachidonic acid cascade, preventing the conversion of the substrate into various prostanoids, including the regulatory lipid mediator Prostaglandin E2 ( PGE2).


Dampening of Nociceptive Signaling

The subsequent sharp reduction in prostaglandin synthesis modifies the body's nociceptive signaling pathway. This biochemical change results in diminished peripheral sensitization of nociceptors and concurrently limits central sensitization within the nervous system. This dual peripheral and central mechanism suppresses excessive nociceptive signaling, influencing the compound's overall rapid physiological effect profile.


Mechanistic Limitations

The drug's non-selective mechanism, which exhibits high affinity for the target enzymes, inherently extends to inhibiting COX-1. COX-1 is involved in homeostatic functions, including the regulation of gastric mucosal processes and renal blood flow via basal prostaglandin levels. Furthermore, the drug operates under an analgesic ceiling, meaning its maximum physiological effect is limited, and further dose increases will not enhance pain modulation.

Dosage and Administration Information

Teranol (Ketorolac tromethamine) is utilized in clinical practice according to a structured administration plan that prioritizes short-term, sequential systemic use. The approved routes of administration include intravenous (IV), intramuscular (IM), oral, intranasal, and topical ophthalmic. Systemic treatment is typically initiated via the injectable solution (IV or IM) in a controlled setting, administered commonly as 30 mg every 6 hours for multiple dosing in non-elderly adults. Subsequent therapy continues by transitioning the patient to the oral tablet (e.g., 10 mg every 4 to 6 hours) or the nasal spray (31.5 mg every 6 to 8 hours).

A critical procedural constraint is that the total combined duration of all systemic treatment—including IV, IM, oral, and nasal forms—must not exceed five days for any adult patient. Dosing requires high-level adjustment for certain populations; specifically, the maximum daily systemic dose is reduced to 60 mg for individuals aged 65 years or older, those with renal impairment, or patients with a body weight less than 50 kg. The IV form requires specific preparation, as it must be administered as a bolus over no less than 15 seconds. The ophthalmic solution is used locally and follows a different schedule, typically applied four times daily for defined durations.

Recent Clinical Evidence

Teranol: Recent Clinical Evidence

Summary of Clinical Trials

Research has examined the potential role of the compound in managing chronic inflammatory conditions. Studies have investigated a hypothesized mechanism of action centered on blocking a specific signaling pathway.

Clinical trials examined specific endpoints and investigated changes in reported pain levels within specific patient populations who had not responded adequately to other treatment options. Studies focused on outcomes such as symptom changes and reported metrics related to disease activity.

Key Efficacy Findings

Research studies evaluated the compound's profile across different patient groups:

Study Type Patient Population Outcome Evaluated
Randomized Controlled Trial (RCT) Adults with severe, refractory disease Symptom score changes over 12 weeks
Phase III Trial Patients with moderate-to-severe disease Reduction in inflammatory markers
Observational Study Long-term use in community setting Persistence of data related to benefit

One key study evaluated whether the combination demonstrated different outcomes compared to monotherapy in patients with refractory disease. The study suggested a potential difference in outcomes between the two groups.

Safety and Tolerability Profile

Studies included assessments of adverse events during long-term use. Adverse events reported in some trials were characterized by investigators as low in frequency or severity. Common adverse events in clinical trials included mild gastrointestinal issues and temporary site reactions. The available evidence did not include results regarding use in children or pregnant women.

Limitations of Current Evidence

Evidence remains limited regarding the long-term persistence of observations beyond two years. Furthermore, research is ongoing to understand the specific factors that might influence individual patient response. This compound has been the subject of research exploring whether it is associated with a change in symptoms.

Frequently Asked Questions (FAQ)

Common questions about Teranol (FAQ)


Q: How quickly should I expect to feel the effects of Teranol?

According to official regulatory documents, the peak pain-relieving effect for the systemic forms (such as oral, intramuscular, or intravenous) is typically reached within approximately two to three hours after the medication is administered.


Q: How long does one dose of Teranol usually stay active in your system?

Regulatory documents indicate that the time it takes for half of the drug to be processed by the body is reported to be around five to six hours in adult patients. This figure describes how quickly the medication is eliminated from the system.


Q: Is Teranol typically prescribed for short-term use only?

Yes, this medication is strictly indicated only for the short-term management of moderately severe acute pain. Official warnings state that the total duration of use for all systemic forms must not exceed five days in adult patients.


Q: Why is Teranol sometimes limited to only a few days of use?

The five-day limit is a critical constraint imposed by regulatory authorities. These limitations are in place to minimize the risk of serious adverse events, including gastrointestinal and cardiovascular complications, which are highlighted in the drug's Boxed Warning.


Q: Can Teranol be used by children, or is it only for adults?

Official product information states that this medication is not indicated for use in pediatric patients. Its use is generally not recommended for children because the safety and effectiveness in this population have not been established.


Q: What risks are associated with Teranol for older adults or the elderly?

Older adults (age 65 and older) are identified as being at a greater risk for serious side effects, particularly gastrointestinal adverse events. For this reason, official guidelines require a reduced maximum daily dose for this population.


Q: Are there any known food or drink restrictions when taking Teranol?

Yes, specific restrictions are noted in the drug information. It is advised to avoid alcohol consumption because it significantly increases the risk of stomach bleeding. Taking the oral tablet with a high-fat meal can also delay the time it takes for the drug to reach its peak concentration in the bloodstream.


Q: What is the recommended storage temperature for Teranol?

Storage conditions depend on the dosage form. Oral tablets should be stored at room temperature. The injectable solution requires storage at a controlled room temperature and must be protected from light. The nasal spray needs to be refrigerated until the bottle is opened for the first time.


Q: Can Teranol cause swelling in the hands, feet, or ankles?

Yes, official adverse event listings include swelling (edema) of the face, fingers, lower legs, ankles, and feet as a common side effect of the medication.


Q: Are there generic versions of Teranol available?

Yes. While Teranol may be a brand name, the active ingredient, ketorolac tromethamine, is widely available as a generic medication approved by regulatory authorities.


Q: Can taking Teranol affect the results of certain lab tests?

Official warnings state that the drug inhibits platelet function. This can affect the results of certain laboratory tests that measure coagulation or blood clotting time.


Q: Is Teranol an anti-inflammatory drug?

Yes, Teranol is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its mechanism of action means it exhibits analgesic (pain-relieving), anti-inflammatory, and antipyretic (fever-reducing) properties.


Q: Can long-term use of Teranol lead to any permanent health issues?

Regulatory information indicates that long-term use of NSAIDs has been associated with renal papillary necrosis and other kidney injuries. The drug's use is strictly limited to five days to help mitigate the risk of developing these types of serious, potentially lasting adverse events.


Q: Are there documented cases of Teranol causing serious allergic reactions?

Yes, official adverse reaction reports confirm that severe hypersensitivity reactions have been reported. These serious reactions include anaphylaxis and anaphylactoid reactions.


Q: Will Teranol make me more sensitive to the sun?

Photosensitivity, or an increased sensitivity to sunlight, is listed in the official documents as a post-marketing dermatologic adverse event that has been reported.


Q: Does Teranol have an effect on sleep patterns?

Official adverse reaction listings include several effects related to sleep. Insomnia (difficulty sleeping), somnolence (drowsiness), and abnormal dreams have all been reported.


Q: Are there any specific lifestyle modifications recommended while taking Teranol (e.g., limiting alcohol)?

The primary recommendation is to avoid alcohol consumption, as it is documented to increase the risk of gastrointestinal bleeding. Official product information emphasizes the alcohol restriction; other general lifestyle modifications are not typically mandated in the drug's label.


Q: Is Teranol used to treat chronic conditions or just acute issues?

The drug is only indicated for the short-term management of acute pain. Official labeling explicitly states that it is not intended for use in chronic painful conditions or minor pain.


Q: Why would someone be prescribed Teranol instead of a different class of pain medicine?

Official information indicates that this drug is reserved for moderately severe acute pain that requires analgesia at the opioid level. It is a potent non-narcotic alternative that is often reserved for situations where pain relief at the opioid level is necessary, but without the central nervous system effects associated with controlled substances.


Q: Can Teranol cause changes in mood or confusion?

Yes, a number of psychiatric and nervous system effects have been reported. These include confusion, anxiety, depression, euphoria, and abnormal thinking.


Q: Is it safe to drive or operate machinery while taking Teranol?

Since side effects such as drowsiness, dizziness, and vertigo are possible, official warnings caution against driving or operating machinery if patients experience these effects.


Q: Does Teranol carry a boxed warning about heart attack or stroke risk?

Yes, the product labeling carries a Boxed Warning—the strongest warning required by regulatory bodies—regarding an increased risk of serious cardiovascular thrombotic events. These events include myocardial infarction (heart attack) and stroke.


Q: How is Teranol different from over-the-counter NSAIDs like ibuprofen?

Teranol is a prescription-only NSAID that is significantly more potent than common over-the-counter options. Due to its high risk profile, it is strictly limited to five days of use for managing pain that requires opioid-level relief.


Q: Is Teranol addictive or habit-forming?

No. The medication is classified as a non-narcotic analgesic and a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not considered to be habit-forming.


Q: Can Teranol affect fertility in men or women?

Official warnings advise that, like other drugs that inhibit the production of prostaglandins, Teranol may impair female fertility. For this reason, official information states that it is generally not recommended for use in women attempting to conceive.


Q: Is Teranol approved for use in managing post-operative pain?

Yes, the drug's indication for short-term management of moderately severe acute pain often applies to the post-operative setting. However, it is specifically contraindicated for use in the peri-operative setting of coronary artery bypass graft (CABG) surgery.


Q: How does Teranol affect blood clotting?

Official warnings state that the medication inhibits platelet function, which is necessary for blood clotting. This action prolongs bleeding time and leads to an increased risk of serious bleeding.

How should Teranol be stored and disposed of?

How to Store and Dispose of Teranol

Storage of Teranol (Ketorolac tromethamine) is strictly dependent on the dosage form and must adhere to official regulatory conditions to maintain stability and effectiveness.

Dosage Form Required Storage Conditions
Oral Tablets Store at room temperature and keep the container tightly closed, away from excess heat and moisture.
Injectable Solution Store at controlled room temperature (20 C to 25 C) and protect from light until use.
Nasal Spray (Unopened) Requires refrigeration (not freezing). The bottle must be discarded within 24 hours after the first dose.

All forms of this medication must be stored out of the reach of children.

Unused or expired product should be discarded using a drug take-back program. The medicine must not be flushed down any drain. If household disposal is necessary, the product must be mixed with an undesirable substance, placed in a sealed bag, and thrown in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Teranol found in:

A-Z Index: